

REGENERATION TECHNOLOGIES INC  
Form 425  
January 17, 2008

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT**

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 17, 2008

---

**TUTOGEN MEDICAL, INC.**

(Exact Name of Registrant as Specified in Charter)

**Florida**  
(State or Other Jurisdiction

of Incorporation)

**001-16-069**  
(Commission File Number)

**59-3100165**  
(I.R.S. Employer

Identification No.)

**13709 Progress Boulevard, Box 19**

**Alachua, Florida 32615**

(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code: **(386) 462-0402**

N/A

(Former Name or Former Address, if Changed Since Last Report)

## Edgar Filing: REGENERATION TECHNOLOGIES INC - Form 425

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**ITEM 8.01 OTHER EVENTS.**

On January 17, 2008, Tutogen Medical, Inc. ( Tutogen ) and Regeneration Technologies, Inc. ( RTI ) issued a press release announcing that with the proposed merger of the two companies, RTI will ask its shareholders to approve a new company name, RTI Biologics, Inc., at the special meeting of the stockholders of RTI scheduled for February 27, 2008. The stock will continue to trade on the Nasdaq Global Market under the symbol RTIX.

A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

**ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.**

(d) Exhibits.

99.1 Press release dated January 17, 2008.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: January 17, 2008

**TUTOGEN MEDICAL, INC.**

/s/ L. Robert Johnston, Jr.  
L. Robert Johnston, Jr.  
Chief Financial Officer

EXHIBIT INDEX

<b>Exhibit Number</b>	<b>Description</b>
99.1	Press release dated January 17, 2008.